Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

In a bid to claw back $2.15 billion, the struggling pharmaceutical giant Bayer CEO is doing away with middle managers and 99% of the company’s 1,362-page corporate handbook, allowing nearly ...

Bayer is looking to accelerate its patient ... related side effects to be detected much earlier. The German pharmaceutical company has tied up with professional services firm Genpact for the ...

Notably, the company warned that 2025 will be weaker ... Sales of glyphosate-based herbicides declined by 19% YoY. Meanwhile, Bayer's Pharmaceutical division has delivered mixed performance.

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

(Reuters) -A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic ...

Compared with the same month last year, the European Union imported significantly more pharmaceutical products from Russia in ...

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...

The Ministry of Planning and Investment, the Ministry of Foreign Affairs, and FPT Corporation co-hosted a working breakfast in Davos, Switzerland on January 22 to discuss the future and opportunities ...

Bayer (BAYGn.DE), opens new tab will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in ...